Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JS 207

Next Previous
Drug Profile

JS 207

Alternative Names: JS-207

Latest Information Update: 22 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DotBio
  • Developer Shanghai Junshi Biosciences
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Liver cancer; Non-small cell lung cancer; Triple negative breast cancer

Most Recent Events

  • 17 Oct 2025 Shanghai Junshi Biosciences plans a phase II/III clinical trial for Non-small cell lung cancer (Neoadjuvant therapy, Late-stage disease)
  • 16 Oct 2025 The US FDA approves IND application for Non-small cell lung cancer (Neoadjuvant therapy, Late-stage disease)
  • 17 Sep 2025 Phase-II clinical trials in Triple-negative-breast-cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, First-line therapy, Combination therapy) in China (IV) (NCT07045311)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top